Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 17/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818502 | 0.81 | DRD4 (0.77) | DRD4KDM4EALDH1A1HTT | |
| SCHEMBL4825126 | 0.76 | DRD4 (0.74) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL4824080 | 0.76 | DRD4 (0.74) | DRD4DRD2KDM4EALDH1A1GRM2 | |
| SCHEMBL4823946 | 0.76 | DRD4 (0.69) | DRD4DRD2NPC1GAAKDM4E | |
| SCHEMBL4819196 | 0.74 | DRD4 (0.76) | DRD4DRD2KDM4EALDH1A1HTT | |
| SCHEMBL4823304 | 0.74 | DRD4 (0.76) | DRD4DRD2NPC1GAAHTR1A | |
| SCHEMBL4826073 | 0.74 | GAA (0.70) | DRD4DRD2NPC1GAAKDM4E | |
| SCHEMBL4823546 | 0.70 | DRD4 (0.77) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL4820628 | 0.67 | DRD4 (0.40) | DRD4DRD2NPC1KDM4EALDH1A1 | |
| SCHEMBL5157052 | 0.67 | HTT (0.84) | DRD4DRD2NPC1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265249-A1 | Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction | ABBVIE INC. | 2007-11-15 | — | — | US | disclosed |
| US-7057042-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, HSD17B11 | DRD4 1401/4885DRD2 1129/4885NPC1 1338/4885 |
| US-20070265249-A1 | Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction | CYP19A1, CYP17A1, HSD17B11 | DRD4 102/4885DRD2 66/4885NPC1 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.